Table 4.
Baseline characteristics of patients treated according to SOC vs shortened treatment.
| Variable | Standard of care N = 18 | Shortened treatment N = 11 | p value | |
|---|---|---|---|---|
| Demographics | Age (Mean ± SD) | 56 ± 16·3 | 49.4 ± 14.7 | 0.27 |
| Female, N (%) | 8 (44.4%) | 5 (45.5%) | 1.00 | |
| Fibrosis | METAVIR 3/4, N (%) | 5 (27.8%) | 2 (18.2%) | 0.68 |
| Laboratory at baseline | ALT U/L (Mean ± SD) | 65.5 ± 38.7 | 40.7 ± 12.7 | 0.05 |
| Total Bilirubin mg/dL (Mean ± SD) | 0.70 ± 0.60 | 0.56 ± 0.18 | 0.45 | |
| Albumin g/dL (Mean ± SD) | 4.4 ± 0.21 | 4.6 ± 0.36 | 0.12 | |
| Creatinine mg/dL (Mean ± SD) | 0.83 ± 0.26 | 0.89 ± 0.38 | 0.63 | |
| Hb g/dL (Mean ± SD) | 13.9 ± 1.2 | 14.8 ± 1.6 | 0.11 | |
| PLT 106/mm6 (Mean ± SD) | 213 ± 69 | 212 ± 55 | 0.96 | |
| HCV RNA IU/mL (median and interquartile range) | 6.46 (5.92–6.66) | 5.88 (5.22–6.35) | 0.044 |
SD, standard deviation; SOC, standard of care; ALT, alanine aminotransferase; Hb, hemoglobin; PLT, platelets; HCV, hepatitis C virus; RNA, ribonucleic acid.